


Media	Lianhe Zaobao	Date	6 Nov 03
Section			



CordLife today announced that it had successfully closed its Series B round with an investment of S\$7 million. The total investment in CordLife to date has been S\$11.4 million.

The funds will be used to expand its business base in China, Australia and the US. It will also be used to fund Phase I and II clinical trials in ex vivo stem cell and T cell expansion. These trials will be conducted in collaboration with the US Food & Drug Administration (FDA) and the Australian government. These trials will begin when the relevant regulatory approvals have been granted, and are expected to last about 12 months.